Lexaria’s DehydraTECH formulation delivers over tenfold CBD to bloodstream than conventional industry formulations

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) announced Wednesday that animal testing proved the company’s DehydraTECH technology delivers cannabinoids (CBD) to the bloodstream “more quickly and effectively” than conventional industry CBD edible formulation designs that combine CBD with medium chain triglyceride (MCT) oils such as coconut oil.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The Kelowna-headquartered company’s disruptive DehydraTECH technology can be applied to foods, beverages, oral suspensions, tablets and capsules.

READ: Lexaria Bioscience gains after announcing cannabinoid R&D project is underway

On March 20, Lexaria started a series of animal studies with multiple objectives, including gaining a better understanding of how edible forms of cannabinoids enter the bloodstream.

In the first animal study, Lexaria compared its standard DehydraTECH formulation that combines cannabinoids with long-chain fatty acids (LCFA) using Lexaria’s patented dehydration processing technique to a concentration-matched formulation utilizing coconut oil which is a commonly used MCT oil in the cannabis edibles industry.

Lexaria has consistently postulated that the use of MCT oil in edibles is less effective for purposes of cannabinoid delivery optimization than its patented DehydraTECH LCFA formulations.

Initial results from the studies showed:

• The DehydraTECH formulation delivered measurable quantities of cannabidiol into the bloodstream in as little as two minutes

• Lexaria’s technology delivered more CBD to the bloodstream in 15 minutes than conventional medium chain triglyceride (MCT) oil-based control formulations did in 60 minutes

• The area under the curve (AUC) for Lexaria’s patented DehydraTECH formulation was 389% more than the MCT oil control formulation

• Lexaria’s DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles

Although the studies tested only for CBD delivery, Lexaria said it has “every reason to believe that virtually identical results would have been achieved” if THC was instead the cannabinoid under examination, consistent with subjective human clinical studies Lexaria’s partners have conducted with edible THC products.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Story by ProactiveInvestors